Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer

Affiliation

• ¹ Christoph Springfeld, MD, PhD, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Markus W. Büchler, MD, FACS (hon), FRCS (hon), FASA(hon), Botton-Champalimaud Pancreatic Cancer Center, Champalimaud Foundation, Lisbon, Portugal; and John P. Neoptolemos, MA, MB, BChir, MD, FRCS, Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany.